Leukemia and lymphoma: In acute myeloid leukemia (AML), bone marrow stem cells (BMSCs) increase the expression of PAK1, resulting in the activation of ERK1/2 signaling to promote drug resistance through modulating the apoptotic pathway [64]. Here, MAPK3 is linked to acute myeloid leukemia.